Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Schering-Plough announces top-line boceprevir results

Schering-Plough announces top-line boceprevir results

5th August 2008

Schering-Plough has announced the publication of top-line results from a phase II study of boceprevir in genotype 1 treatment-naive hepatitis C patients.

The company said the compound showed a high rate of sustained response, with 74 per cent of patients achieving SVR 12 following 48-weeks of beceprevir-based combination therapy.

These patients received four weeks of treatment with Pegintron (peginterferon alfa-2b) and Rebetol (ribavirin) before the addition of boceprevir to their treatment regimen.

In comparison, patients administered only with Pegintron and Rebetol throughout the 48-week period saw a 38 per cent SVR 12 rate.

Furthermore, a high SVR 24 rate was also seen in the 28-week treatment arm for patients receiving boceprevir.

The company said it would begin enrolling patients in phase III studies for the compound this summer.

Paul Kwo, associate professor of medicine and medical director for liver transplantation of the Department of Medicine at Indiana University School of Medicine, said: “These top-line results with boceprevir are very exciting, especially given that genotype 1 is the most common and hardest to treat form of hepatitis C.”

He added the compound was well-tolerated in patients, including those in the longer 48-week treatment arms.

In April 2008, Schering-Plough said interim results of the study of the investivational oral hepatitis C protease inhibitor were encouraging, especially given the response following a shorter course of treatment.

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.